Our CEO Pascal Soriot shares our strong 2024 performance with continued double-digit growth and scientific progress across all Therapy Areas. We're also pleased to announce that AstraZeneca’s total annual dividend has increased by 7% to $3.10 per share and will further increase in 2025. This momentum reflects the great work of our teams to deliver for people, society and the planet. #WhatScienceCanDo
This year we are excited to celebrate our 25th anniversary with our teams around the world! We are pleased to report 2023 was another year of double-digit growth and scientific progress, with investments in exciting areas of science that lay the foundations for continued long-term success. We are committed to unlocking the power of what science can do for people, society and the planet.